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Abstract
Reduction of extracellular ferricyanide by intact cells reflects the activity of an as yet unidentified trans-plasma membrane
oxidoreductase. In human erythrocytes, this activity was found to be limited by the ability of the cells to recycle intracellular
ascorbic acid, its primary trans-membrane electron donor. Ascorbate-dependent ferricyanide reduction by erythrocytes was
partially inhibited by reaction of one or more cell-surface sulfhydryls with p-chloromercuribenzene sulfonic acid, an effect
that persisted in resealed ghosts prepared from such treated cells. However, treatment of intact cells with the sulfhydryl
reagent had no effect on NADH-dependent ferricyanide or ferricytochrome c reductase activities of open ghosts prepared
from treated cells. When cytosol-free ghosts were resealed to contain trypsin or pronase, ascorbate-dependent reduction of
extravesicular ferricyanide was doubled, whereas NADH-dependent ferricyanide and ferricytochrome c reduction were
decreased by proteolytic digestion. The trans-membrane ascorbate-dependent activity was also found to be inhibited by
reaction of sulfhydryls on its cytoplasmic face. These results show that the trans-membrane ferricyanide oxidoreductase is
limited by the ability of erythrocytes to recycle intracellular ascorbate, that it does not involve the endofacial NADH-
dependent cytochrome b5 reductase system, and that it is a trans-membrane protein that contains sensitive sulfhydryl groups
on both membrane faces. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Virtually all cells appear capable of reducing ex-
tracellular ferricyanide to ferrocyanide [1]. This ac-
tivity has been linked to several important cellular
functions, including stimulation of cell growth and
di¡erentiation [2,3], reduction and uptake of ferric
iron [1], and protection against an extracellular oxi-
dant stress [4]. Since ferricyanide does not penetrate
the cell membrane [5], its reduction requires either
that electrons be transferred from the cell interior
across the plasma membrane, or that the cells release
a substance capable of reducing ferricyanide. NADH
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has long been considered a source of intracellular
electrons for ferricyanide reduction [1,6]. Extracellu-
lar ferricyanide reduction is also enhanced in propor-
tion to the cellular content of ascorbic acid [6,7].
Moreover, in cell types as diverse as human erythro-
cytes [8], pulmonary artery endothelial cells [9], and
HL-60 cells [10], ascorbate at physiologic concentra-
tions appears to be the major electron donor to the
trans-membrane activity. Although ascorbate-in-
duced ferricyanide reduction was initially considered
to be due to direct reduction of ferricyanide by as-
corbate that had leaked from the cells [6], subsequent
work has shown that intracellular ascorbate donates
electrons to an as yet unidenti¢ed trans-plasma mem-
brane ferricyanide oxidoreductase activity [4,7,10].
Ascorbate-dependent ferricyanide oxidoreductase
activity is thought to be mediated at least in part
by a protein or enzyme, since reduction is saturable
with increasing concentrations of extracellular ferri-
cyanide or intracellular ascorbate [7,10], and since it
is inhibited by poorly penetrant protein reagents such
as diazobenzene sulfonic acid (DABS) [11] and
p-chloromercuribenzene sulfonic acid (PCMBS)
[7,10,11]. However, it is possible that other factors
account for apparent saturation of ferricyanide re-
duction, and that these reagents penetrate the cell
membrane or lack speci¢city for proteins. It is also
unknown whether the oxidoreductase spans the
membrane or involves the prominent NADH-de-
pendent cytochrome b5 reductase system on the cy-
toplasmic membrane face. Regarding the latter, Van
Duijn et al. [10] recently reported that ferricyanide
reduction by ascorbate-free HL-60 cells, which is pre-
sumably NADH-dependent, is more sensitive to in-
hibition by PCMBS than is ferricyanide reduction in
ascorbate-loaded cells.
In contrast to NADH-dependent ferricyanide re-
duction, which can be assessed in open membranes
and in puri¢ed preparations, study of ascorbate-de-
pendent activity requires separation of the two
reactants, because of the rapid direct reduction of
ferricyanide by ascorbate. Therefore, the present
studies were carried out in intact human erythrocytes
and in resealed erythrocyte ghosts, with the goal of
establishing the substrate dependence, kinetics, and
susceptibility to protein reagents of both membrane
faces of the trans-membrane ascorbate-dependent
ferricyanide reductase. The major ¢ndings are that
ascorbate-dependent ferricyanide reduction is limited
more by the ability of cells to recycle ascorbate
than by electron-transfer capacity, that the exposed
cytoplasmic acceptor of ascorbate electrons involves
a protein that is distinct from the cytochrome b5
reductase complex, and that function of this
protein requires one or more endofacial sulfhydryl
groups.
2. Materials and methods
2.1. Materials
DHA, 2,2,6,6-tetramethyl-4-hydroxy-piperidine-N-
oxyl (Tempol), and tridecylamine were from Aldrich
(Milwaukee, WI). All other reagents were purchased
from Sigma (St. Louis, MO). DABS was synthesized
as described previously [11] and stored under nitro-
gen for up to a week before use without loss of
activity.
2.2. Erythrocyte and erythrocyte ghost preparation
Human erythrocytes were prepared from heparin-
ized blood that had been drawn from normal vol-
unteers. Erythrocytes were obtained by three cen-
trifugation washes in 10 vols. of phosphate-bu¡ered
saline (PBS), which consisted of 140 mM NaCl and
12.5 mM Na2HPO4 in deionized water, adjusted to
pH 7.4. The bu¡y coat of white cells was removed
with each wash.
Body leaky and ‘pink’ resealed erythrocyte ghosts
were prepared as described by Steck and Kant [12].
Resealed hemoglobin-free or ‘clear’ ghosts were pre-
pared according to a previously described method
[13] with the following minor modi¢cations. Open
or leaky erythrocyte ghosts were prepared initially
to be free of visible hemoglobin contamination.
These were incubated with mixing for 5 min on ice
in 5 mM sodium phosphate bu¡er, pH 8.0, that con-
tained 1 mM MgSO4 and agents as noted. While the
ghosts were on ice, NaCl was added to a ¢nal con-
centration of 150 mM. The ghost suspension was
warmed to 37‡C and incubated for an additional
hour. The ghosts were washed three times by centrif-
ugation at 13 000Ug in ice-cold PBS and taken for
assays as noted.
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2.3. Measurement of ascorbate, GSH, and
K-tocopherol in cells and in resealed ghosts
Ascorbate was measured in intact cells following
cell lysis and ultra¢ltration as previously described
[14]. Prior to some experiments, endogenous erythro-
cyte ascorbate was depleted by three repetitive treat-
ments with 1 mM Tempol [14]. For assay of intra-
vesicular ascorbate in resealed ghosts, the ghosts
were lysed with an equal volume of 0.4% (v/v) Tri-
ton-X100 prior to ultra¢ltration and subsequent as-
say of ascorbate as described for erythrocytes. The
GSH content of erythrocytes was measured with the
£uorometric assay of Hissin and Hilf [15].
The K-tocopherol content of erythrocytes was
measured as follows. Packed cells (0.2 ml) were
mixed with an equal volume of 0.5% pyrogallol (w/
v) in water. This was followed by 0.2 ml of reagent
alcohol (95% ethanol:5% isopropanol, v/v) with vig-
orous mixing. Heptane (0.4 ml) was added, and the
lysate was vortexed for at least 1 min. The lysate was
microfuged and an aliquot of the clear upper heptane
layer was removed and taken to dryness under a
stream of nitrogen. The residue was dissolved in
0.2^0.4 ml of a 1:1 mixture of ethanol and methanol
for assay by HPLC with electrochemical detection.
Samples were chromatographed in the isocratic mode
on a Waters DeltaPak C18 column (300 Wm, 5 W) that
was preceded by a 4-mm guard column of the same
packing material. The mobile phase was 95% meth-
anol and 5% water containing 20 mM sodium per-
chlorate. Detection of K-tocopherol was accom-
plished by a modi¢cation of the reduction^
oxidation method described by Takeda, et al. [16].
An ESA model 5020 guard cell, which was preceded
by a graphite in-line ¢lter, was placed just after the
analytical column and set in the reducing mode at
30.5 V. This was followed by an ESA model 5011
analytical cell that was used for detection, with the
¢rst electrode in the analytical cell set at 30.5 V, and
the second detecting electrode set at +0.6 V. At a
£ow rate of 1 ml/min, K-tocopherolquinone was de-
tected at 4.3^4.6 min, Q-tocopherol at 5.6^5.9 min,
and K-tocopherol at 6.1^6.4 min. The assay sensitiv-
ity for K-tocopherol was 2^5 pmol/sample.
Erythrocyte and ghost concentrations of ascor-
bate, K-tocopherol, and GSH are expressed relative
to the water content of packed erythrocytes, or 70%
of the packed cell volume [6].
2.4. Assay of extracellular oxidant reduction
Reduction of extracellular ferricyanide to ferrocya-
nide by erythrocytes was measured with the method
of Avron and Shavit [17] as previously described [4],
following incubation of 5% cells for the indicated
time at 37‡C in PBS that contained 5 mM D-glucose
and 1 mM potassium ferricyanide. A correction was
made for absorbance of medium from cells incubated
in the absence of ferricyanide.
Reduction of oxidized cytochrome c (ferricyto-
chrome c) was measured by incubating control and
ascorbate-loaded cells at a 20% hematocrit in PBS
that contained 5 mM D-glucose and 100 WM ferricy-
tochrome c for 30 min at 37‡C. The cells were pel-
leted in a microfuge and the absorbance of an ali-
quot of the medium was measured at 550 nm.
Correction was made for interfering substances re-
leased from the cells, including ascorbate, by carry-
ing out paired cell incubations that did not contain
ferricytochrome c, incubating the medium from such
cells for 10 min at 37‡C with 100 WM ferricyto-
chrome c, measuring the absorbance at 550 nm in
an aliquot of that medium, and subtracting this read-
ing from the value obtained when cells were incu-
bated with ferricytochrome c.
Reduction of ferric citrate by control and ascor-
bate-loaded erythrocytes was measured by incubat-
ing cells at a 5% hematocrit in PBS that contained
5 mM D-glucose, 80 WM bathophenanthroline disul-
fonate (BPS), and the indicated concentration of fer-
ric citrate for 30 min at 37‡C. Soluble ferric citrate
was prepared by dissolving ferric chloride to a 1 mM
concentration in a 5-fold molar excess of trisodium
citrate. Reduction of Fe3 to Fe2 was measured as
the BPS chelate of Fe2 at 535 nm in the supernatant
from the cell incubations. Correction for release of
ascorbate and other interfering substances by the
cells was made as described for assay of ferricyto-
chrome c reductase activity.
For assay of ferricyanide reduction by erythrocyte
ghosts that had been resealed to contain ascorbate
and other agents, aliquots of ghosts prepared from
0.1 or 0.2 ml of packed erythrocytes were incubated
BBAMEM 77657 1-9-99
J.M. May, Z.-c. Qu / Biochimica et Biophysica Acta 1421 (1999) 19^31 21
with 1 mM ferricyanide at 37‡C in a total volume of
1 ml. At 10 min, the ghosts were pelleted in a micro-
fuge at (13 000Ug for 1 min) and duplicate 100 Wl
aliquots of the supernatant were taken for assay of
ferrocyanide. Paired ghost samples were also incu-
bated in the absence of ferricyanide for 10 min, the
ghosts were pelleted in the microfuge, and the super-
natant was then incubated with 1 mM ferricyanide
for another 10 min at 37‡C. Duplicate 100-Wl ali-
quots of this sample were taken for assay of ferro-
cyanide and the readings in these samples were sub-
tracted from those of the ¢rst sample to correct for
background due to incubation with the ghosts and
for any ascorbate that had leaked from the ghosts.
For ‘clear’ or washed resealed ghosts this correction
was typically 30^50% of the experimental reading,
and for standard ‘pink’ resealed ghosts it was about
10%.
2.5. Data and statistical analysis
Data are shown as mean þ S.E. Curve-¢tting was
carried out by non-linear least-squares regression us-
ing the graphics program Origin 5.0 (Microcal Soft-
ware, Northampton, MA). Statistical signi¢cance
was assessed by one- or two-way analysis of variance
using the statistics program Sigmastat 2.0 (Jandel
Scienti¢c, St. Louis, MO).
3. Results
3.1. Basal and ascorbate-dependent erythrocyte
ferricyanide reduction
To assess di¡erences in ascorbate-dependent and
-independent ferricyanide reduction in intact erythro-
cytes, cells were loaded with increasing concentra-
tions of DHA, and both the cellular ascorbate con-
tent and ferricyanide reduction were measured. As
shown in Fig. 1A, DHA loading increased intracel-
lular ascorbate concentrations, which in turn en-
hanced the initial rates of ferricyanide reduction in
a saturable fashion. At the higher DHA concentra-
tions ferricyanide reduction was linear for only about
5^10 min (results not shown), so a time point of
5 min was used in these experiments to obtain an
estimate of the initial rate of reduction. The maximal
ascorbate-stimulated ferricyanide reduction was al-
most 20-fold that of the basal rate (59 þ 8 nmol (ml
cells)31 min31 in basal cells compared to 1125 þ 100
nmol (ml cells)31 min31 in cells incubated with 320
WM DHA). After subtraction of the basal rate, the
data were ¢t to an hyperbolic model, which resulted
in an apparent Km of 1.8 þ 0.4 mM, and a predicted
maximal rate of 1988 þ 290 nmol min31 (ml cells)31.
However, most of the observed saturation of ferri-
cyanide reduction is due to a decrease in intracellular
ascorbate induced by ferricyanide. As shown in the
inset to Fig. 1A, intracellular ascorbate concentra-
tions measured after 5 min of ferricyanide exposure
had fallen to about 20% of the initial values for
ascorbate concentrations of 140 WM or higher (re-
sulting from DHA loading concentrations of v 50
WM). On the other hand, the cells were able to main-
tain basal ascorbate concentrations despite the oxi-
dant stress induced by ferricyanide. Based on the
extent of ferricyanide reduction, and on the meas-
ured initial and ¢nal ascorbate contents, the cells
recycled cellular ascorbate about 2^3 times over the
5-min period of ferricyanide reduction. These results
show that the ascorbate recycling capacity of eryth-
rocytes, although substantial, limits the activity of
the trans-membrane oxidoreductase. This further
suggests that the trans-membrane oxidoreductase ac-
tivity operates well below its capacity at physiologic
ascorbate concentrations within the cells (30^80 WM).
The marked stimulation of ferricyanide reduction
by ascorbate-loading shown in Fig. 1A was observed
in cells that contained endogenous ascorbate. To
more directly compare rates of ascorbate-dependent
and -independent ferricyanide reduction, cells were
¢rst depleted of endogenous ascorbate by several
treatments with the cell-penetrant nitroxide, Tempol,
which removes about 80% of erythrocyte ascorbate
without a¡ecting K-tocopherol or GSH [14]. As
shown in Fig. 1B, ferricyanide reduction in ascor-
bate-depleted cells was very low compared to that
in ascorbate-loaded cells, although both showed sat-
uration with increasing amounts of ferricyanide. At
least with regard to the ascorbate-loaded cells, the
apparent saturation of ferricyanide reduction is likely
due at least in part to exceeding the capacity of cel-
lular ascorbate recycling. Also, despite the use of
short incubation times (5 min), low concentrations
of cells (5%) and 100 WM DHA, it can be calculated
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that at the lowest ferricyanide concentrations 75^
83% of extracellular ferricyanide was reduced by
the DHA-treated cells. Thus, changes in the concen-
trations of both substrates for this reaction prevent
any conclusions to be drawn regarding whether the
saturation of the ascorbate-dependent reaction re-
lates to saturation of the trans-membrane oxidore-
ductase. Nonetheless, these results highlight marked
Fig. 1. Ascorbate-dependent reduction of ferricyanide in intact erythrocytes. (A) Erythrocytes at a 10% hematocrit were incubated for
15 min at 37‡C with 5 mM D-glucose and freshly prepared DHA (0, 20, 40, 80, 160, 320 WM) in PBS. The cells were washed by cen-
trifugation in 5 vols. of PBS, and aliquots were taken for assay of the intracellular ascorbate concentration and for measurement of
ferricyanide reduction during a 5-min incubation. Data are shown from four experiments, with the solid line representing an hyper-
bolic ¢t to the data following subtraction of the basal rate. Inset: the cellular content of ascorbate at the end of the ferricyanide incu-
bation was measured in three experiments, and expressed as a percent of the initial ascorbate concentration. (B) Erythrocytes that had
been depleted of endogenous ascorbate with Tempol were incubated without (circles) or with 100 WM DHA (squares) as described for
A, washed three times by centrifugation, and incubated for another 5 min at 37‡C with the indicated initial concentration of ferricya-
nide. The cells were pelleted and aliquots of the supernatants were taken for assay of ferrocyanide during a 5-min incubation. Data
are shown from three experiments, with the solid lines indicating ¢ts to hyperbolic models.
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di¡erences in the kinetics of ferricyanide reduction in
ascorbate-loaded compared to ascorbate-depleted
cells.
3.2. Erythrocyte reduction of other electron acceptors
The ability of erythrocytes to transfer electrons to
extracellular acceptors other than ferricyanide was
evaluated with regard to ascorbate dependence, since
such a comparison might indicate how many transfer
systems are operative. As shown in Table 1, compar-
isons were made between reduction of ferricyanide,
ferricytochrome c, and ferric iron. Reduction of fer-
ricytochrome c was measured directly, and reduction
of Fe3 was detected by a change in UV absorbance
on chelation of Fe2 by bathophenanthroline disul-
fonate (BPS) outside the cells. The rates of both ac-
tivities were found much lower than that of ferricya-
nide reduction (Table 1, ¢rst column), even though
the latter was not an initial rate, since measurements
were made at 30 min. Ascorbate that has leaked
from cells will directly reduce each of the oxidants,
so control incubations were performed to assess and
correct for such a leak, as shown in the second and
third columns of Table 1, respectively. E¥ux of as-
corbate could account for only 1.5% of the observed
rate of ferricyanide reduction. In contrast, there was
no signi¢cant cellular reduction of ferricytochrome c
following correction of ascorbate leak (Table 1).
Comparison of these results provides compelling evi-
dence that ascorbate-dependent ferricyanide reduc-
tion is not due to leak of ascorbate from the cells.
In contrast to ferricytochrome c, there remained a
small but signi¢cant e¡ect of intracellular ascorbate
to reduce extracellular Fe3, even after correction for
ascorbate leak. The dose-dependence of this e¡ect
was evaluated in ascorbate-depleted cells, with the
results shown in Fig. 2. Reduction of Fe3 was sat-
urable with increasing concentrations of ferric cit-
rate. When ¢t to hyperbolic models, the apparent
Km values for basal (8 þ 3 WM) and ascorbate-stimu-
lated (60 þ 11 WM) ferric iron reduction di¡ered, as
did the calculated maximal rate of ferric ion reduc-
tion (1.3 þ 0.1 for basal versus 13.9 þ 1.4 nmol min31
(ml cells)31). Intracellular ascorbate concentrations
at the highest ferric citrate concentration (80 WM)
were unchanged (results not shown), indicating that
the observed plateau in reduction is due to the trans-
membrane process and not to changes in ascorbate.
Whereas ascorbate-dependent ferric iron reduction is
markedly greater than reduction in ascorbate-de-
pleted cells, it undergoes saturation in a manner
that di¡ers from that observed for ascorbate-depend-
ent ferricyanide reduction.
Table 1
Reduction of extracellular oxidants by ascorbate-loaded erythrocytes
Oxidant Cells Supernatant Di¡erence
Ferricyanide 336 þ 43a 5 þ 2 331 þ 43
Ferricytochrome c 7 þ 1 7 þ 1 0
Fe3-citrate 16 þ 2a 5 þ 1 11 þ 1
Cells at a 20% hematocrit were incubated with 100 WM DHA and 5 mM D-glucose for 15 min at 37‡C, then washed three times by
centrifugation. Reduction assays were carried out as described in Section 2, all for 30 min. All units are nmol min31 (ml eryth-
rocytes)31. Data are from at least four experiments for each treatment.
aP6 0.05 compared to the rate of reduction in the cell supernatant.
Fig. 2. Ascorbate-dependent reduction of ferric citrate. Erythro-
cytes that had been depleted of ascorbate by Tempol treatment
were incubated at a 15% hematocrit for 15 min at 37‡C in the
absence (circles) or presence (squares) of 100 WM DHA, washed
three times in PBS, and assayed for reduction of the indicated
concentration of ferric citrate. Results from three experiments
are shown, with ¢ts indicated by the solid lines to hyperbolic
models.
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3.3. Sensitivity of ferricyanide reduction to poorly
permeant inhibitors
To assess the extent to which the trans-membrane
activity is exposed on the cell surface, the sensitivity
of ferricyanide reduction to poorly penetrant cova-
lent inhibitors was examined. Agents likely to inter-
act only with extracellular groups were chosen to
increase selectivity for trans-plasma membrane activ-
ities. As shown in Table 2, ascorbate-stimulated fer-
ricyanide reduction was inhibited 30^50% by
PCMBS, TNBS, DABS, and tetrathionate, but was
una¡ected by DTNB. Each of the agents that
showed inhibition also had some e¡ect on cellular
GSH, ascorbate, or K-tocopherol (Table 2), but
none caused hemolysis. The loss of ascorbate and/
or GSH in response to treatment of cells with the
inhibitory agents could indicate that the agent did
not remain outside the cells during incubation.
That is, some of the decrease in ferricyanide reduc-
tion observed with these agents could be due to their
reaction with intracellular proteins. Of these agents,
tetrathionate and PCMBS are already known to en-
ter erythrocytes slowly on the anion transporter
[18,19]. If e¡ects of the sulfhydryl reagents are due
to intracellular reactions, blockade of their entry on
the anion transporter with 4,4P-diisothiocyanodihy-
drostilbene-2,2P-disulfonic acid (DIDS) should pre-
vent the e¡ect [18].
To determine whether an agent had entered the
cells on the anion transporter, DIDS was included
during loading of the cells with ascorbate, with the
results shown in the second column of Table 2.
Treatment with DIDS alone did not a¡ect either
basal or ascorbate-stimulated ferricyanide reduction
(results not shown). DIDS largely prevented the in-
hibition by tetrathionate, decreased that due to
PCMBS by about 30%, but had no e¡ect on inhi-
bition by DABS or TNBS. These results suggest that
Fig. 3. Inhibition of ascorbate-dependent ferricyanide reduction
by PCMBS. Cells that had been depleted of endogenous ascor-
bate by treatment with Tempol were incubated at 37‡C in PBS
at a 10% hematocrit with 25 WM DIDS, 5 mM D-glucose, and
either without (circles) or with 100 WM DHA (squares). At 15
min, PCMBS was added to the indicated ¢nal concentration
and the incubation was continued for another 15 min. Aliquots
of mixed cells and bu¡er were removed, washed three times in
PBS, and taken for measurement of ferricyanide reduction dur-
ing a 30-min incubation. Data from 7 experiments are shown.
Table 2
E¡ects of sulfhydryl reagents on ascorbate-dependent ferricyanide reduction and cell antioxidants
Agent Ferricyanide reduction Ascorbate K-Tocopherol GSH
DIDS (25 WM): (3) (+) (3) (3) (3)
PCMBS (200 WM) 0.47 þ 0.03a 0.66 þ 0.04a 0.89 þ 0.04a 0.96 þ 0.16 0.95 þ 0.05
TNBS (1 mM) 0.56 þ 0.07a 0.66 þ 0.04a 0.51 þ 0.07a 0.94 þ 0.23 0.9 þ 0.09
DABS (300 WM) 0.06 þ 0.002a 0.07 þ 0.01a 0.7 þ 0.09a 0.06 þ 0.01a 1.07 þ 0.08
Tetrathionate (50 mM) 0.68 þ 0.03a 0.87 þ 0.08 0.92 þ 0.07 0.99 þ 0.23 0.39 þ 0.03a
DTNB (3 mM) 1.06 þ 0.02 1.00 þ 0.01 1.09 þ 0.1 0.91 þ 0.26 0.96 þ 0.03
Cells at a 10% hematocrit were incubated with 200 WM DHA with or without DIDS as indicated in PBS containing 5 mM D-glucose.
After 15 min at 37‡C, the agents were added to the concentrations shown, and the incubations were continued for another 15 min.
The cells were washed three times and ferricyanide reduction was determined over 30 min. Antioxidant concentrations were deter-
mined in basal cells treated with and without the agents under the same conditions. All results are shown as percent of the corre-
sponding value in untreated control cells from 3^6 experiments. Control values were: ferricyanide reduction, 291 þ 31 nmol (ml eryth-
rocytes)31 min31 ; ascorbate, 59 þ 10 WM; K-tocopherol, 3.9 þ 0.6 WM; and GSH, 2.0 þ 0.2 mM.
aP6 0.05 compared to the appropriate control.
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the e¡ect of tetrathionate is due to reaction with an
intracellular sulfhydryl necessary for function of the
oxidoreductase, whereas most of the e¡ect of
PCMBS is due to interaction with a cell-surface pro-
tein sulfhydryl. Treatment with DIDS was without
e¡ect on the decreases in intracellular ascorbate in-
duced by DABS, TNBS, or PCMBS (results not
shown). This could indicate that these agents caused
a trans-membrane oxidant stress that lowered intra-
cellular ascorbate. Since TNBS and DABS substan-
tially depleted ascorbate and/or K-tocopherol, further
experiments were carried out with PCMBS, using
pretreatment with DIDS to prevent uptake of
PCMBS. The concentration-dependence of PCMBS
inhibition of erythrocyte ferricyanide reduction was
examined with the studies shown in Fig. 3.
Inhibition of ascorbate-dependent ferricyanide re-
duction by PCMBS in DIDS-pretreated cells oc-
curred rapidly, and was essentially complete in about
15 min (results not shown). To assess the e¡ects of
PCMBS on ascorbate-independent ferricyanide re-
duction, cells were again largely depleted of endoge-
nous ascorbate by repetitive treatments with Tempol.
In ascorbate-depleted, DIDS-treated cells, increasing
amounts of PCMBS caused only about a 20% de-
crease in ferricyanide reduction (Fig. 3). On the other
hand, in ascorbate-loaded cells there was a progres-
sive inhibition of ferricyanide reduction to about
40% of control over the range of PCMBS concentra-
tions used. These di¡erences in sensitivity to inhibi-
tion by PCMBS suggest that basal and ascorbate-
mediated ferricyanide reduction are not due to the
same activity.
Since ascorbate-dependent ferric citrate reduction
by erythrocytes di¡ered in several respects from fer-
ricyanide reduction, the e¡ects of PCMBS on ferric
citrate reduction were tested. However, there was no
e¡ect of PCMBS up to concentrations of 0.2 mM on
ferric citrate reduction. This also suggests that these
two activities are not mediated by the same process.
3.4. Trans-membrane ferricyanide reduction in
erythrocyte ghosts
Resealed ‘pink’ erythrocyte ghosts were studied to
determine whether inhibition of trans-plasma mem-
brane reduction of ferricyanide by PCMBS persists
after cell disruption or whether it requires cytosolic
components. When present during the resealing
phase, both ascorbate and NADH are trapped with-
in these ghosts and can support reduction of extra-
vesicular ferricyanide [20]. As shown in Fig. 4, in-
Table 3
Lack of e¡ects of PCMBS treatment of intact cells on cytochrome b5 reductase
Activity Control PCMBS PCMBS+DIDS
Ferricyanide reductase 76 þ 15 80 þ 12 87 þ 6
Ferricytochrome c reductase 8.8 þ 1.4 6.6 þ 0.7 8.7 þ 1.5
Cells at a 10% hematocrit were incubated with or without 25 WM DIDS and 5 mM D-glucose for 15 min at 37‡C, followed by addi-
tion of 200 WM PCMBS where noted for another 15 min. The cells were then washed three times by centrifugation and taken for
preparation of leaky ghosts. Reduction assays were carried out as described in Section 2. Units are nmol min31 (mg ghost protein)31.
Data are from four experiments for each treatment.
Fig. 4. Ferricyanide reduction in resealed erythrocyte ghosts
loaded with increasing concentrations of ascorbate or NADH.
Resealed ghosts were prepared to contain the measured ascor-
bate concentrations noted on the upper x-axis, and their ability
to reduce ferricyanide in the presence of 2 U/ml ascorbate oxi-
dase was determined. The results from four experiments are
shown, with the ¢t to an hyperbolic model shown by the solid
line. NADH-dependent reduction was measured in three experi-
ments at the loading concentrations of NADH shown on the
lower x-axis.
BBAMEM 77657 1-9-99
J.M. May, Z.-c. Qu / Biochimica et Biophysica Acta 1421 (1999) 19^3126
creasing amounts of trapped ascorbate enhanced fer-
ricyanide reduction in a saturable manner. The initial
intravesicular ascorbate concentration at which ferri-
cyanide reduction was half-maximal was 0.65 þ 0.1
mM, and the predicted maximal e¡ect was 110 þ 7
nmol (ml ghosts)31 min31. In comparison to the re-
sults of Fig. 1A, it is evident that the rate of ferri-
cyanide reduction at the same initial intracellular as-
corbate concentration is about 9-fold greater in the
cells than in the ghosts. Contributing to this di¡er-
ence is the fact that these ghosts are unable to recycle
ascorbate, so that intravesicular ascorbate concentra-
tions will fall even during short incubations. In con-
trast to the results observed with ascorbate, increas-
ing amounts of NADH caused little increase in
ferricyanide reduction (Fig. 4). These results were
not altered by inclusion of an NADH-regenerating
system consisting of lactate and lactate dehydrogen-
ase (results not shown).
To further compare the mechanism(s) of ascor-
bate- and NADH-dependent ferricyanide reduction,
ghosts prepared from PCMBS-treated cells were
loaded with ascorbate and assayed for changes in
their ability to reduce extravesicular ferricyanide.
As shown in Fig. 5, even with DIDS pretreatment,
PCMBS inhibited ferricyanide reduction by the
ghosts 22%. Although this less than the e¡ect ob-
served in intact cells (see Fig. 3), it is nonetheless
signi¢cant. This shows that the e¡ect of PCMBS
persists after cell lysis, and that it involves a compo-
nent of the ghost membrane rather than a cytosolic
component.
In contrast to trans-membrane ascorbate-depend-
ent ferricyanide reduction, there was no e¡ect of
PCMBS treatment of DIDS-treated cells on either
NADH-dependent ferricyanide reductase or on ferri-
cytochrome c reductase activities in leaky erythrocyte
ghosts that were prepared from the cells (Table 3).
Fig. 6. E¡ects of proteolytic enzymes and DTNB on resealed
clear erythrocyte ghost ascorbate-dependent ferricyanide reduc-
tase activity. Clear erythrocyte ghosts were prepared to contain
4 mM ascorbate and the indicated concentration of DTNB (A,
n = 5), pronase (B, n = 3), or trypsin (C, n = 6). Ferricyanide re-
duction by the ghosts was measured with correction for ascor-
bate leakage. Units are nmol min31 (ml ghosts)31.
Fig. 5. Ferricyanide reduction in resealed erythrocyte ghosts
prepared from PCMBS-treated cells. Erythrocytes at a 10%
hematocrit were preincubated at 37‡C in PBS that contained 25
WM DIDS and 5 mM D-glucose. At 15 min the indicated con-
centrations of PCMBS were added. After another 15 min, the
cells were lysed and resealed ghosts were prepared to contain
4 mM ascorbate for incubation in the resealed ghost ferri-
cyanide reduction assay. Data are shown from six experiments.
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Ferricyanide reductase activity was about 10-fold
greater than ferricytochrome c reductase activity.
Whereas PCMBS inhibition of ascorbate-dependent
ferricyanide reduction persists in resealed ghosts, no
residual e¡ect of external PCMBS reaction is evident
in open ghost membranes using NADH as an elec-
tron donor. This suggests that the ascorbate-depend-
ent trans-membrane activity and the bulk of the
membrane-bound NADH-dependent reductase activ-
ities are di¡erent.
3.5. E¡ects of reaction of endofacial sites with protein
reagents
To gain additional insight into the components of
the trans-membrane ferricyanide reductase that are
exposed on the cytosolic membrane face, the e¡ects
of proteolytic enzymes and DTNB were assessed in
resealed and leaky erythrocyte ghosts. It was not
possible to use standard resealed erythrocyte ghosts
in these experiments, since the agents to be studied
would react directly with cytosolic components and
hemoglobin that are still present during the resealing
process. Therefore, hemoglobin- and cytosol-free re-
sealed ghosts were prepared to contain either DTNB,
trypsin or pronase. In preliminary studies, it was
determined that ferricyanide reduction in clear re-
sealed ghosts loaded with 4 mM ascorbate was linear
for at least 5 min (results not shown), and this time
taken for subsequent studies. Although DTNB had
no e¡ect on ascorbate-dependent ferricyanide reduc-
tion in intact cells (Table 2), it decreased this activity
in resealed clear ghosts by about 50% (Fig. 6A). On
the other hand, both pronase (Fig. 6B) and trypsin
(Fig. 6C) tripled ascorbate-dependent ferricyanide re-
duction by the ghosts. Neither enzyme had any ef-
fects on ascorbate-dependent ferricyanide reduction
in intact cells (results not shown). Furthermore, the
proteolytic enzymes did not increase ascorbate leak
out of the ghosts (results not shown), and this leak
was corrected for in a paired sample as described in
Section 2. Together, the results of Fig. 6 suggest that
the ascorbate-dependent ferricyanide reductase activ-
ity of the erythrocyte membrane has sensitive protein
components exposed on the cytoplasmic face of the
cell membrane.
Di¡erent results were observed when leaky eryth-
rocyte ghosts were treated directly with DTNB or
trypsin, washed by centrifugation, and assayed for
NADH-dependent ferricyanide and ferricytochrome
c reductase activities. As shown in Fig. 7, both activ-
ities were inhibited about 50% by the same range of
trypsin concentrations that stimulated ascorbate-de-
pendent ferricyanide reduction in resealed ghosts
(Fig. 6C). Low concentrations of DTNB were more
potent in inhibiting both activities than were the
same DTNB concentrations in inhibiting extracellu-
lar ferricyanide reduction (see Fig. 6A). This dichot-
omy in the e¡ects of trypsin and DTNB in resealed
and open ghosts strongly suggests that the ascorbate-
dependent trans-membrane activity does not corre-
spond to the major cytosolic NADH-dependent re-
ductase.
Fig. 7. Inhibition of ferricyanide and cytochrome c reductase
activities by trypsin and DTNB in open ghosts. Leaky erythro-
cyte ghosts (0.2^0.4 mg/ml) were incubated with the indicated
concentrations of trypsin (A) or DTNB (B) for 1 h at 37‡C in
5 mM phosphate bu¡er, pH 8.0. The ghosts were washed three
times by centrifugation and aliquots were taken for assay of
ferricyanide (circles) and ferricytochrome c (squares) reductase
activities. Data from three experiments with each agent are
shown.
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4. Discussion
Ferricyanide reduction by erythrocytes and prob-
ably by nucleated cells is mediated by an as yet un-
identi¢ed trans-membrane oxidoreductase activity.
The present studies provide additional support for
the notions that ascorbate is the major intracellular
electron donor for this activity in erythrocytes and
that a reactive exofacial sulfhydryl is required for
activity. New ¢ndings regarding the ascorbate-de-
pendent trans-membrane oxidoreductase are that it
di¡ers in several respects from basal or ascorbate-
independent activity, that its activity is limited by
intracellular recycling of ascorbate, that it is not in-
volved in reduction of ferric iron, that it does not
correspond to the cytochrome b5 reductase system
present on the endofacial membrane surface, and
that it has exposed protein on its cytoplasmic face
that contains one or more reactive sulfhydryl groups.
Erythrocytes have very low rates of ascorbate-in-
dependent ferricyanide reductase activity (Fig. 1). In
cultured pulmonary artery endothelial cells [9] and
HL-60 tumor cells [10] that contain little or no en-
dogenous ascorbate, basal activity is also 10% or less
of maximal ascorbate-dependent activity. Further-
more, NADH supported ferricyanide reduction in
resealed erythrocyte ghosts to only a fraction of the
rate observed for ascorbate, even with correction for
leak of ascorbate out of the ghosts (Fig. 4). These
results, and the ¢nding of di¡erent inhibitory curves
by PCMBS in basal and ascorbate-loaded cells (Fig.
3) support the previous conclusion derived from
study of HL-60 cells [10] that these two activities
are mediated by di¡erent proteins.
Ascorbate-dependent ferricyanide reduction was
both enhanced and limited by the ability of the cells
to recycle ascorbate. Although erythrocytes were able
to maintain physiologic intracellular ascorbate con-
centrations (30^60 WM) in the face of ferricyanide
treatment, at initial intracellular ascorbate concentra-
tions of 140 WM and greater, ascorbate fell back to
basal levels following even a short 5-min ferricyanide
treatment (Fig. 1A, insert). This suggests that the
trans-membrane ferricyanide reductase does not limit
ferricyanide reduction over a physiologic range of
ascorbate concentrations, despite apparent saturation
with increasing initial intracellular ascorbate concen-
trations. Such considerations probably also apply to
previous demonstrations of the saturability of ferri-
cyanide reduction in response to increasing intracel-
lular ascorbate concentrations in nucleated cells
[9,10]. In other words, the capacity for ferricyanide
reduction may depend more on the ability of cells to
recycle ascorbate than on the ability of the cells to
transfer electrons across the plasma membrane.
Although ascorbate may be the intracellular sub-
strate for the trans-membrane oxidoreductase, the
natural extracellular electron acceptor is unknown.
A trans-membrane oxidoreductase has been impli-
cated in reduction of both ferricytochrome c [21]
and methemoglobin [22]. However, when e¥ux of
ascorbate is taken into consideration, neither eryth-
rocytes (Table 1) nor endothelial cells [9] reduce fer-
ricytochrome c. A similar explanation probably also
accounts for reduction of methemoglobin by eryth-
rocytes over several hours of incubation at 37‡C [22].
Erythrocytes did reduce ferric iron in an ascorbate-
dependent manner, even after correction for ascor-
bate that had leaked from the cells (Table 1 and Fig.
2). A role for the trans-membrane ferricyanide oxi-
doreductase in transferrin-independent reduction and
uptake of iron has long been a consideration [6].
Nevertheless, the rate of ferric iron reduction by
erythrocytes was both saturable and very low com-
pared to that of ferricyanide, and it was not inhibited
by PCMBS. This makes it unlikely that the same
activity mediates both ferricyanide and ferric iron
reduction. We were recently unable to show that in-
tracellular ascorbate enhances extracellular ferric
iron reduction with the same assay in human mono-
cytic U-937 cells, despite the presence of ascorbate-
dependent ferricyanide reduction in those cells [23].
Previous studies in erythrocytes [7] and in HL-60
cells [10] showed inhibition of the trans-membrane
ascorbate-dependent oxidoreductase by PCMBS,
leading to the suggestion that this activity is medi-
ated by a protein with one or more reactive exofacial
sulfhydryls. On the other hand, PCMBS enters eryth-
rocytes at appreciable rates on the anion transporter
[18,19], so that the observed inhibition by PCMBS
could be due to interaction with internal sulfhydryls.
Nevertheless, our results support the original conten-
tion, since even after blockade of anion transport
with DIDS, ferricyanide reduction was still decreased
by 30^40% in intact erythrocytes (Table 2 and Fig.
3). Other reagents were either ine¡ective (DTNB),
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highly penetrant (tetrathionate), or less speci¢c in
their interactions with the cells (DABS and TNBS).
DABS has been shown to inhibit basal ferricyanide
reduction in intact erythrocytes by about 35% [11],
and we found a similar e¡ect on ascorbate-dependent
reduction. However, we also found that DABS se-
verely depleted membrane K-tocopherol (Table 2). It
is possible that loss of K-tocopherol caused part of
the e¡ect of DABS to inhibit ferricyanide reduction.
For example, K-tocopherol incorporated into lipo-
somes has been shown to mediate ferricyanide reduc-
tion by ascorbate trapped within the liposomes
[24,25], and we found that K-tocopherol added to
erythrocyte ghosts enhances trans-membrane ferri-
cyanide reduction by ascorbate [20]. Nevertheless,
the results with PCMBS do suggest the presence of
a sensitive exofacial sulfhydryl on the trans-mem-
brane enzyme.
Several ¢ndings in this study indicate that the as-
corbate-dependent trans-plasma membrane ferricya-
nide reductase does not involve the ubiquitous
NADH:ferricyanide reductase of isolated plasma
membranes [1]. Most of the ferricyanide reductase
activity of open erythrocyte ghost membranes is
mediated by cytochrome b5 reductase [26]. Both
this enzyme [27] and its associated cytochrome b5
[28] are restricted to the cytoplasmic membrane
face and thus are not accessible to cell-impermeant
reagents. We found that pretreatment of intact cells
with PCMBS resulted in persistent inhibition of as-
corbate-dependent ferricyanide reduction in resealed
ghosts (Fig. 5), but failed to inhibit either ferricya-
nide or ferricytochrome c reductase activities in open
erythrocyte ghost membranes when intracellular ef-
fects of PCMBS were prevented by DIDS (Table 3).
Second, since NADH is the preferred substrate for
cytochrome b5 reductase [26], the low rates of
NADH- compared to ascorbate-dependent ferricya-
nide reduction in resealed erythrocyte ghosts (Fig. 4)
argue against NADH as an intracellular electron do-
nor. Third, incorporation of proteolytic enzymes
within resealed ghosts enhanced the trans-membrane
ferricyanide reductase activity (Fig. 6), whereas direct
treatment of leaky ghosts with the same range of
enzyme concentrations decreased both ferricyanide
and ferricytochrome c reductase activities (Fig. 7).
Finally, DTNB treatment of open ghosts was more
e¡ective in blocking NADH-dependent ferricyanide
and ferricytochrome c reductase activities (Fig. 7)
than DTNB within resealed ghosts was in preventing
ascorbate-dependent trans-membrane ferricyanide re-
duction (Fig. 6A). These results provide compelling
evidence that the trans-membrane ascorbate-depend-
ent ferricyanide reductase does not have the cyto-
chrome b5 reductase system as its intracellular com-
ponent.
There remains the possibility that cytochrome b5
reductase may participate in preserving ascorbate as
a substrate for the trans-membrane enzyme. Ferri-
cyanide generates intracellular AFR in intact eryth-
rocytes as a result of a one-electron reduction medi-
ated by the trans-membrane enzyme [29].
Microsomal cytochrome b5 reductase has been
shown to reduce the AFR to ascorbate in an
NADH-dependent manner [30]. By reducing the
AFR to ascorbate, the erythrocyte cytochrome b5
reductase could help to recycle ascorbate and aug-
ment the activity of the trans-membrane enzyme. In
this regard, we have previously shown that the e¡ects
of ascorbate and NADH are additive in enhancing
ferricyanide reduction by resealed ghosts [8].
The cytoplasmic portion of the trans-membrane
ascorbate-dependent ferricyanide reductase has ex-
posed protein with a reactive sulfhydryl. Thus, pro-
teolytic enzymes trapped within resealed ghosts en-
hanced extravesicular ferricyanide reduction (Fig. 6),
but trypsin was without e¡ect on this activity in in-
tact cells. Similarly, when resealed within ghosts,
DTNB caused up to a 50% inhibition of ascorbate-
dependent ferricyanide reduction (Fig. 6A), but did
not inhibit ferricyanide reduction by intact cells (Ta-
ble 1). DTNB, which undergoes disul¢de interchange
reactions, is highly speci¢c for protein sulfhydryls.
These results suggest that the involved protein spans
the plasma membrane, and that it has a reactive
endofacial sulfhydryl that is required for full activity.
Of possible candidates for the trans-membrane ox-
idoreductase, negative results with DIDS in this
work and with cytochalasin B in a previous study
[7] rule-out the anion and glucose transporters, re-
spectively. A trans-membrane NADH:ferricyanide
reductase has been puri¢ed from human erythrocyte
membranes [31]. This enzyme was found to di¡er
from the cytochrome b5 reductase with regard to
size, kinetics, prosthetic group, and in the presence
of about 6% glycosylation by weight [31]. The latter
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¢nding supports the contention that this protein is a
trans-membrane ferricyanide reductase, although
there is no evidence that it can use ascorbate as an
intracellular electron donor. As recently reviewed
[32], the present results suggest that ascorbate-de-
pendent ferricyanide reduction is mediated by such
a trans-membrane protein, and that sulfhydryls on
both membrane faces may aid in its puri¢cation
and identi¢cation.
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